Bavarian Nordic beats Q3 revenue expectations

Nov 13 (Reuters) – Danish vaccine maker Bavarian Nordic reported higher than expected revenue ​for the third ‌quarter on Friday, boosted by a continued strong performance in its travel health business. Bavarian’s outlook increasingly ‌hinges ​on whether ⁠strong rabies demand ⁠proves durable and whether newer products such as Vimkunya can offset volatility in the ​preparedness-vaccine business. • Q3 revenue came to 1.81 ⁠billion Danish crowns ($267.81 ⁠million) against year-earlier 1.80 ​billion • It beat analysts’ average ​estimate of 1.69 billion in ‌a company-provided consensus • Bavarian reiterated the full-year guidance it upgraded in October, driven ⁠by higher US rabies vaccine sales • Travel health revenue rose 22% ⁠to ‌1.14 billion crowns ⁠against company-provided consensus of ​1.02 ‌billion, driven by continued ​strong ⁠RabAvert/Rabipur sales and supported by the continued launch of Vimkunya ($1 = 6.7585 Danish crowns) (Reporting by Elviira Luoma, editing by ​Matt Scuffham)